202 related articles for article (PubMed ID: 3123602)
1. Current controversies in the use of selegiline hydrochloride.
Lees AJ
J Neural Transm Suppl; 1987; 25():157-62. PubMed ID: 3123602
[TBL] [Abstract][Full Text] [Related]
2. Selegiline for Parkinson's disease.
Calesnick B
Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
[TBL] [Abstract][Full Text] [Related]
3. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
Rinne UK
J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
[TBL] [Abstract][Full Text] [Related]
4. Selegiline in the early and late phases of Parkinson's disease.
Csanda E; Tárczy M
J Neural Transm Suppl; 1987; 25():105-13. PubMed ID: 3123597
[TBL] [Abstract][Full Text] [Related]
5. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
6. Experience with selegiline in the treatment of Parkinson's disease.
Poewe W; Gerstenbrand F; Ransmayr G
J Neural Transm Suppl; 1987; 25():131-5. PubMed ID: 3123599
[TBL] [Abstract][Full Text] [Related]
7. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Tetrud JW; Langston JW
J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
[TBL] [Abstract][Full Text] [Related]
8. R-(-)-deprenyl and parkinsonism.
Yahr MD
J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
[TBL] [Abstract][Full Text] [Related]
9. Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
Lander CM; Lees A; Stern G
Clin Exp Neurol; 1979; 16():197-203. PubMed ID: 121706
[TBL] [Abstract][Full Text] [Related]
10. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Birkmayer W; Birkmayer GD
J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
Youdim MB
J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
[TBL] [Abstract][Full Text] [Related]
12. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
Golbe LI; Duvoisin RC
J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
[TBL] [Abstract][Full Text] [Related]
13. L-deprenyl in the treatment of Parkinson's disease.
Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
[TBL] [Abstract][Full Text] [Related]
14. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
[No Abstract] [Full Text] [Related]
15. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
Amato L; Nava L; Rizzo M; Piccoli F
Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
[No Abstract] [Full Text] [Related]
16. (-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
Giovannini P; Martignoni E; Piccolo I; Pacchetti C; Grassi MP; Nappi G; Caraceni T
J Neural Transm Suppl; 1986; 22():235-46. PubMed ID: 3097258
[TBL] [Abstract][Full Text] [Related]
17. The role of MAO-b inhibitors in the treatment of Parkinson's disease.
Ruggieri S; Stocchi F; Denaro A; Baronti F; Agnoli A
J Neural Transm Suppl; 1986; 22():227-33. PubMed ID: 3097257
[TBL] [Abstract][Full Text] [Related]
18. (-)Deprenyl in the treatment of decompensated Parkinson's disease.
Csanda E; Tárczy M; Takáts A
J Neural Transm Suppl; 1986; 22():247-52. PubMed ID: 3097259
[TBL] [Abstract][Full Text] [Related]
19. New approaches in the use of selegiline for the treatment of Parkinson's disease.
Lees AJ; Frankel J; Eatough V; Stern GM
Acta Neurol Scand Suppl; 1989; 126():139-45. PubMed ID: 2515719
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
